784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion | Zendy

AI Assistant Blog Pricing

784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies – results of a phase I trial expansion

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.